Shaily Engineering Plastics has emerged as a critical partner in the global scramble to deliver semaglutide, the blockbuster anti-obesity and diabetes drug. According to reports from Moneycontrol, the company's stock surge is driven by its role in delivering semaglutide through precision-engineered injector pens. One of its customers has already received approval in Canada for generic semaglutide with Shaily's device, which the company designed, holds intellectual property for, and manufactures in India. As TradingView News reports, semaglutide, sold under brand names such as Ozempic and Wegovy, is administered through an injector pen, a precision-engineered device that ensures accurate dose. The approval serves as validation of Indian engineering capabilities and demonstrates the company's full-stack capability in drug delivery devices.
Shaily's financial performance reflects the success of its semaglutide strategy. As reported by Moneycontrol, the company's FY26 revenue came in at ₹990.7 crore, up 26 percent from the year-ago period. Net profit surged 83 percent to ₹169.9 crore and EBITDA margins expanded by 630 basis points to 29 percent. The healthcare vertical, driven by pen injectors, surged 139 percent, more than doubling its revenue contribution to 40 percent and becoming the company's primary growth engine. The stock has surged more than 50 percent in the past year, significantly outperforming the broader market. According to TradingView News, this performance comes after the company took a contrarian bet on drug-delivery devices years earlier, investing three to five years in developing its pen technology instead of licensing it.
Shaily is making significant investments to capitalize on the semaglutide opportunity. According to Moneycontrol, the company is raising capacity to up to 85 million pens annually in India, with additional lines coming online this fiscal. It is also building a 75-million-pen capacity plant in Abu Dhabi as part of a diversification strategy. The company has already invested about ₹400 crore in India and plans to spend ₹2,50,350 crore in Abu Dhabi, taking overall investments to around ₹7,50,800 crore. The expansion is backed by strong visibility, with the company disclosing a ₹423-crore order for pen injectors alongside multiple ongoing customer engagements. As TradingView News reports, Shaily is working with multiple customers in India and globally and expects demand to grow as more markets go off patent.
UBS has identified Shaily as its 'top midcap idea' for 2026, expecting the company to benefit from the launch of generic semaglutide. As reported by Moneycontrol, UBS expects volumes to ramp up, with potential to exceed 55 million pens annually this fiscal and further scaling as new markets open up. However, there are risks associated with the business model, including dependence on timely regulatory approvals of partner drugs and execution of complex manufacturing lines. Management acknowledges that production bottlenecks could affect supply in the near term, though the opportunity appears outsized given the company's niche positioning in a market dominated by a handful of global device manufacturers. According to TradingView News, Shaily is rapidly becoming the preferred partner for Indian and global pharma companies racing to launch generics due to the complexity of semaglutide delivery, where the drug and delivery device must be approved together, creating high entry barriers.
